Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
July 22 2016 - 10:58AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon tetracycline chemistry, announced
today that it will host a conference call and live audio webcast on
Thursday, August 4, 2016, at 8:30 AM ET to report second quarter
2016 financial results and provide a corporate update.
The live webcast can be accessed under "Events and
Presentations" in the Investor Relations section of the Company's
website at www.paratekpharma.com.
Domestic investors wishing to participate in the call should
dial: 877-407-9039 and international investors should dial:
201-689-8470. The conference ID is 13641904. Investors can also
access the call at
http://public.viavid.com/index.php?id=120479.
Replays of the call will be available through August 18, 2016.
Domestic investors can access the replay by dialing 877-870-5176
and international investors can access the replay by dialing
858-384-5517. The PIN code to access the replay is 13641904.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of innovative
therapies based upon its expertise in novel tetracycline chemistry.
Paratek's lead product candidate, omadacycline, is the first in a
new class of tetracyclines known as aminomethylcyclines, with
broad-spectrum activity against Gram-positive, Gram-negative and
atypical bacteria. In June 2016 Paratek announced positive efficacy
data in a Phase 3 registration study in ABSSSI demonstrating the
efficacy, safety and tolerability of the once-daily oral and IV
formulations of omadacycline compared to linezolid. A Phase 3
registration study for community acquired bacterial pneumonia
(CABP) comparing omadacycline to moxifloxacin was initiated in
November 2015 and top line data is expected as early as the third
quarter of 2017. A phase 1b study in uncomplicated urinary tract
infections (uUTI) was initiated in May 2016. Omadacycline has
been granted QIDP and Fast Track status by the U.S. Food and Drug
Administration.
Omadacycline is a new once-daily oral and IV, well-tolerated
broad spectrum antibiotic being developed for use as empiric
monotherapy for patients suffering from serious community-acquired
bacterial infections, such as acute bacterial skin and skin
structure infections, community acquired bacterial pneumonia,
urinary tract infections and other community-acquired bacterial
infections, particularly when antibiotic resistance is of concern
to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is
designed to be a well-tolerated, once-daily, oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory
properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the
development and commercialization of sarecycline. Paratek retains
all ex-U.S. rights. Allergan initiated two identical Phase 3
registration studies in December 2014 for sarecycline for the
treatment of moderate to severe acne vulgaris.
For more information, visit www.paratekpharma.com.
CONTACTS:
Media Relations:
Michael Lampe
(484) 575-5040
michael@scientpr.com
Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Sep 2023 to Sep 2024